Linda H Ficociello

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8867322/publications.pdf

Version: 2024-02-01

37 papers	2,893 citations	430442 18 h-index	433756 31 g-index
41 all docs	41 docs citations	41 times ranked	3046 citing authors

#	Article	IF	Citations
1	Regression of Microalbuminuria in Type 1 Diabetes. New England Journal of Medicine, 2003, 348, 2285-2293.	13.9	719
2	Microalbuminuria and the Risk for Early Progressive Renal Function Decline in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2007, 18, 1353-1361.	3.0	325
3	Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 516-524.	3.0	307
4	In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney International, 2010, 77, 57-64.	2.6	231
5	Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-Î²-D-glucosaminidase. Kidney International, 2011, 79, 464-470.	2.6	202
6	High-Normal Serum Uric Acid Increases Risk of Early Progressive Renal Function Loss in Type 1 Diabetes. Diabetes Care, 2010, 33, 1337-1343.	4.3	191
7	Urinary Peptidome May Predict Renal Function Decline in Type 1 Diabetes and Microalbuminuria. Journal of the American Society of Nephrology: JASN, 2009, 20, 2065-2074.	3.0	136
8	Association of Urinary Inflammatory Markers and Renal Decline in Microalbuminuric Type 1 Diabetics. Journal of the American Society of Nephrology: JASN, 2008, 19, 789-797.	3.0	132
9	High-Normal Serum Uric Acid Is Associated with Impaired Glomerular Filtration Rate in Nonproteinuric Patients with Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 706-713.	2.2	130
10	Serum Concentrations of Markers of TNFÎ± and Fas-Mediated Pathways and Renal Function in Nonproteinuric Patients with Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 62-70.	2.2	124
11	Determinants of Progression from Microalbuminuria to Proteinuria in Patients Who Have Type 1 Diabetes and Are Treated with Angiotensin-Converting Enzyme Inhibitors. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 461-469.	2.2	49
12	Serum Levels of Advanced Glycation Endproducts and Other Markers of Protein Damage in Early Diabetic Nephropathy in Type 1 Diabetes. PLoS ONE, 2012, 7, e35655.	1.1	46
13	Cardiac Autonomic Neuropathy and Early Progressive Renal Decline in Patients with Nonmacroalbuminuric Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1136-1144.	2.2	41
14	Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type 1 diabetes. Kidney International, 2013, 83, 1177-1184.	2.6	36
15	Between hyperfiltration and impairment: Demystifying early renal functional changes in diabetic nephropathy. Diabetes Research and Clinical Practice, 2008, 82, S46-S53.	1.1	34
16	Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data. Clinical Nephrology, 2017, 88, 59-67.	0.4	29
17	Slipping Through the Pores: Hypoalbuminemia and Albumin Loss During Hemodialysis. International Journal of Nephrology and Renovascular Disease, 2021, Volume 14, 11-21.	0.8	26
18	One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis. , 2019, 29, 428-437.		23

#	Article	IF	Citations
19	Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide. American Journal of Nephrology, 2018, 47, 153-161.	1.4	20
20	Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide . International Journal of Nephrology and Renovascular Disease, 2019, Volume 12, 1-8.	0.8	18
21	Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1720-1722.	2.2	18
22	Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study. BMC Nephrology, 2019, 20, 396.	0.8	10
23	Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study. Kidney Medicine, 2020, 2, 307-316.	1.0	9
24	Change in glycemic control predicts change in weight in adolescent boys with type 1 diabetes. Pediatric Diabetes, 2003, 4, 162-167.	1.2	7
25	A Score Test for Association of a Longitudinal Marker and an Event with Missing Data. Biometrics, 2010, 66, 726-732.	0.8	7
26	Meeting the Demand for Renal Replacement Therapy during the COVID-19 Pandemic: A Manufacturerâ€™s Perspective. Kidney360, 2021, 2, 350-354.	0.9	7
27	A test for the relationship between a timeâ€varying marker and both recovery and progression with missing data. Statistics in Medicine, 2011, 30, 718-724.	0.8	3
28	Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients. Kidney360, 2020, 1, 263-272.	0.9	3
29	A Comparison of Clinical Parameters and Outcomes over 1 Year in Home Hemodialysis Patients Using 2008K@home or NxStage System One. ASAIO Journal, 2016, 62, 182-189.	0.9	3
30	Global realâ€world data on hemodiafiltration: An opportunity to complement clinical trial evidence. Seminars in Dialysis, 2022, 35, 440-445.	0.7	3
31	Real-World Performance of High-Flux Dialyzers in Patients With Hypoalbuminemia. ASAIO Journal, 2022, 68, 96-102.	0.9	1
32	Antibody Response to the Coronavirus Disease 2019 Ad26.COV2.S Vaccine Among Maintenance Dialysis Patients. Kidney Medicine, 2022, 4, 100409.	1.0	1
33	Switching from highâ€flux dialysis to hemodiafiltration: Costâ€consequences for patients, providers, and payers. Seminars in Dialysis, 2022, , .	0.7	1
34	Effect of Citrate-Acidified Dialysate on Intact Parathyroid Hormone in Prevalent Hemodialysis Patients: A Matched Retrospective Cohort Study. International Journal of Nephrology and Renovascular Disease, 2021, Volume 14, 475-486.	0.8	1
35	MP575SERUM PHOSPHORUS AND PHOSPHATE BINDER PILL BURDEN IN DIABETIC HEMODIALYSIS PATIENTS SWITCHED TO SUCROFERRIC OXYHYDROXIDE AS PART OF ROUTINE CARE. Nephrology Dialysis Transplantation, 2016, 31, i532-i532.	0.4	0
36	FC024REAL-WORLD SAFETY AND EFFECTIVENESS OF SUCROFERRIC OXYHYDROXIDE IN PATIENTS UNDERGOING PERITONEAL DIALYSIS: AN INTERIM ANALYSIS OF THE VERIFIE STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0

#	Article	IF	Citations
37	Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort. International Journal of Nephrology and Renovascular Disease, 2022, Volume 15, 139-149.	0.8	0